Bristol-Myers Squibb

Bristol-Myers Squibb, a US-based pharmaceutical manufacturer, reported total carbon emissions of approximately 2.01 billion kg CO2e in 2024. This comprised Scope 1 emissions of around 206.7 million kg CO2e, Scope 2 emissions (market-based) of about 104.6 million kg CO2e, and Scope 3 emissions of approximately 1.70 billion kg CO2e. This represents a decrease from 2023, where total emissions were roughly 2.12 billion kg CO2e, including Scope 1 emissions of about 208.5 million kg CO2e, Scope 2 (market-based) emissions of approximately 158.4 million kg CO2e, and Scope 3 emissions of around 1.75 billion kg CO2e. In 2022, total emissions stood at roughly 2.14 billion kg CO2e, with Scope 1 emissions at approximately 212.3 million kg CO2e, Scope 2 (market-based) emissions at around 160.6 million kg CO2e, and Scope 3 emissions at approximately 1.77 billion kg CO2e.

Bristol-Myers Squibb has set ambitious climate commitments, with its targets validated by the Science Based Targets initiative (SBTi). The company is committed to reaching net-zero greenhouse gas emissions across its entire value chain by 2050.

For near-term targets, Bristol-Myers Squibb aims to reduce absolute Scope 1 and 2 GHG emissions by 54.6% by 2033, using a 2022 base year. Concurrently, it commits to reducing absolute Scope 3 GHG emissions from fuel and energy-related activities by 54.6% within the same timeframe. Furthermore, the company pledges that 75% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028.

For long-term targets, Bristol-Myers Squibb commits to a 90% reduction in absolute Scope 1 and 2 GHG emissions by 2050 from a 2022 base year. A 90% reduction in absolute Scope 3 GHG emissions is also targeted within the same timeframe. These targets are consistent with reductions required to limit global warming to 1.5°C.